Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Safusidenib · 3 trials · 16 indications
PFS, defined as time from date of randomization to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR or death from any cause, whichever occurs earlier
calculate Percentage and numbers of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed by CTCAE 5.0
PFS is defined as the time from randomization to the date of the first documented disease progression assessed by BICR per RANO 2.0 or death (by any cause in the absence of disease progression).
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR
| Arm | Type | Description |
|---|---|---|
| Safusidenib | EXPERIMENTAL | Safusidenib 250 mg BID |
| Placebo | PLACEBO_COMPARATOR | Placebo BID |
| safusidenib 125mg bid (part 1) | EXPERIMENTAL | safusidenib 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity. |
| safusidenib 250mg bid (part 1) | EXPERIMENTAL | safusidenib 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity. |
| safusidenib 500mg qd (part 1) | EXPERIMENTAL | safusidenib 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity. |
| safusidenib 375mg bid (part 1) | EXPERIMENTAL | safusidenib 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity. |
| safusidenib 500mg bid (part 1) | EXPERIMENTAL | safusidenib 500mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity. |
| safusidenib 250mg bid (Part 2) | EXPERIMENTAL | safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment until disease progression or another reason for discontinuation occurs. |
| placebo (Part 2) | PLACEBO_COMPARATOR | Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs. |
| safusidenib 250mg bid (Part 3) | EXPERIMENTAL | safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment until disease progression or another reason for discontinuation occurs. |
| Name | Type | Description |
|---|---|---|
| Safusidenib | DRUG | Safusidenib administered twice daily as a single agent dosed orally on Days 1 through 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
| Placebo | DRUG | Placebo administered twice daily as a single agent dosed orally on Days 1 through 28 of a 28-day cycle. Participants may continue treatment with placebo until disease progression or another reason for discontinuation occurs. |
Key Inclusion Criteria: * Expected survival of ≥12 months. * At least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection), with the most recent surgery having occurred at least 90 days (or at least 28 days if biopsy only and postoperative changes have resolved per BIC...
Safusidenib is an investigational small molecule being developed for the treatment of IDH1-mutant gliomas, including Grade 2 glioma (astrocytoma or oligodendroglioma) with an IDH1 mutation. It is currently in Phase 3 clinical trials for these indications.
Safusidenib targets and inhibits IDH1, a mutated enzyme involved in cancer metabolism. By inhibiting IDH1, Safusidenib aims to block the production of the oncometabolite 2-hydroxyglutarate, which drives tumor growth in IDH1-mutant gliomas.
Safusidenib is being developed by Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company focused on oncology. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with IDH1-mutant gliomas.
Safusidenib is in Phase 3 clinical development for IDH1-mutant glioma. It has received Fast Track designation from the FDA. The drug is investigational and has not yet been approved for commercial use.
Safusidenib is being evaluated in the SIGMA trial (NCT05303519), a Phase 3 study in IDH1-mutant glioma with an enrollment of 365 participants. Additional trials include NCT07703436, a Phase 2 study in patients who discontinued vorasidenib, and NCT07712757, a Phase 3 study in Grade 2 IDH1-mutant glioma.
No, Safusidenib is not the same as vorasidenib. Safusidenib is a distinct IDH1 inhibitor developed by Nuvation Bio. One of its clinical trials (NCT07703436) specifically enrolls patients with IDH1-mutant glioma who discontinued vorasidenib treatment due to progressive disease.